Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 1, pp 57–64 | Cite as

Role of community pharmacists in the prevention and management of the metabolic syndrome in Kuwait

  • Maram G. KatoueEmail author
  • Abdelmoneim I. Awad
  • Samuel B. Kombian
Research Article

Abstract

Background The metabolic syndrome is a cluster of cardiovascular risk factors and its prevalence is alarmingly high in Kuwait, affecting nearly one third of the adult population. There is lack of information about the role of community pharmacists in the care of patients with the metabolic syndrome. Objective To assess the awareness and opinions of community pharmacists about the metabolic syndrome and identify the services they provide for identification, management and monitoring of patients with the metabolic syndrome. Setting Community pharmacies in Kuwait. Method A descriptive, cross-sectional study was performed on a randomly selected sample of 225 community pharmacists. Data were collected via face-to-face structured interview of the pharmacists using a pre-tested questionnaire. Main outcome measures Pharmacists’ knowledge and views on the metabolic syndrome, monitoring services provided, self-reported practices and perceived effectiveness of the various management interventions for the metabolic syndrome. Results The response rate was 97.8 %. Nine pharmacists claimed to know about the metabolic syndrome, but only one pharmacist could identify the condition correctly. After being given a definition of the metabolic syndrome, 67.7 % of respondents strongly agreed that its prevalence was rising in Kuwait. Nearly two thirds of respondents reported providing height and weight measurement service while 82.7 and 59.5 % of pharmacies provided blood pressure and blood glucose measurements, respectively. Waist circumference and lipid profile measurements were the least provided services (1.8 %). Respondents claimed to be involved in counseling patients on lifestyle modifications including increased exercise (98.1 %) and weight reduction through diet (96.9 %). Most pharmacists were involved in encouraging patients’ adherence with prescribed treatments (98.6 %) and perceived these as the most effective intervention for the management of the metabolic syndrome (95.0 %). Respondents were less involved in monitoring patients’ response to therapy (75.0 %) and documenting patient care services (5.0 %). Conclusion This study revealed significant deficits in awareness among community pharmacists about the metabolic syndrome. Given the proper education and training, community pharmacists could be important front-line contributors to the control of this emerging epidemic in Kuwait.

Keywords

Community pharmacists Kuwait Metabolic syndrome 

Notes

Acknowledgments

We are grateful to the pharmacists who agreed to participate in this study. We thank Dr. Rashed Khazal for his assistance in reaching community pharmacies in Al-Jahra. Those who are interested in using the questionnaire are suggested to write to the corresponding author to obtain a copy.

Funding

None.

Conflicts of interest

Authors have no conflicts of interest with regard to the data produced.

References

  1. 1.
    Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Al Rashdan I, Al Nesef Y. Prevalence of overweight, obesity, and metabolic syndrome among adult Kuwaitis: results from community-based national survey. Angiology. 2010;61(1):42–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Al-Shaibani H, El-Batish M, Sorkhou I, Al-Shamali N, Al-Namash H, Habiba S, et al. Prevalence of insulin resistance syndrome in a primary health care center in Kuwait. Fam Med. 2004;36(8):540.PubMedGoogle Scholar
  6. 6.
    Sorkhou EI, Al-Qallaf B, Al-Namash HA, Ben-Nakhi A, Al-Batish MM, Habiba SA. Prevalence of metabolic syndrome among hypertensive patients attending a primary care clinic in Kuwait. Med Princ Pract. 2004;13(1):39–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Moussa MA, Alsaeid M, Abdella N, Refai TM, Al-Sheikh N, Gomez JE. Prevalence of type 2 diabetes mellitus among Kuwaiti children and adolescents. Med Princ Pract. 2008;17(4):270–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Trinca CE. The pharmacist’s progress toward implementing pharmaceutical care. Am Pharm. 1995;Suppl:13–8.Google Scholar
  9. 9.
    Fornos JA, Andres NF, Andres JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci. 2006;28(2):65–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24(6):677–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc (Wash). 2000;40(2):157–65.Google Scholar
  12. 12.
    Robinson JD, Segal R, Lopez LM, Doty RE. Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practice. Ann Pharmacother. 2010;44(1):88–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Lau R, Stewart K, McNamara KP, Jackson SL, Hughes JD, Peterson GM, et al. Evaluation of a community pharmacy-based intervention for improving patient adherence to antihypertensives: a randomised controlled trial. BMC Health Serv Res. 2010;10:34.PubMedCrossRefGoogle Scholar
  14. 14.
    Olenak JL, Calpin M. Establishing a cardiovascular health and wellness program in a community pharmacy: screening for metabolic syndrome. J Am Pharm Assoc. 2010;50(1):32–6.CrossRefGoogle Scholar
  15. 15.
    Hammad EA, Yasein N, Tahaineh L, bsoul-Younes AM. A randomized controlled trial to assess pharmacist–physician collaborative practice in the management of metabolic syndrome in a university medical clinic in Jordan. J Manag Care Pharm. 2011;17(4):295–303.PubMedGoogle Scholar
  16. 16.
    Matowe L, Al-Kandery AS, Bihzad SM. Pharmacy in Kuwait. Am J Health Syst Pharm. 2003;60(15):1591–2.PubMedGoogle Scholar
  17. 17.
    Awad A, Abahussain E. Health promotion and education activities of community pharmacists in Kuwait. Pharm World Sci. 2010;32(2):146–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Lenth, RV. Java Applets for Power and Sample Size. (2006–2009) (cited Aug 24, 2012). Available from: http://www.stat.uiowa.edu/~rlenth/Power/.
  19. 19.
    World Health Organization: how to investigate drug use in health facilities: Selected drug use indicators (WHO/DAP/93.1). 1993 (cited Aug 30, 2012). Available from: http://apps.who.int/medicinedocs/fr/d/Js2289e/.
  20. 20.
    Snella KA, Canales AE, Irons BK, Sleeper-Irons RB, Villarreal MC, Levi-Derrick VE, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2006;46(3):370–7.CrossRefGoogle Scholar
  21. 21.
    Schneiderhan ME, Batscha CL, Rosen C. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy. 2009;29(8):975–87.PubMedCrossRefGoogle Scholar
  22. 22.
    Benavides S, Kohler LA, Souffrant G. A clinical pharmacist’s role in screening for metabolic syndrome in a rural pediatric ambulatory clinic. J Rural Health. 2011;27(2):184–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee K, Song YM, Sung J. Which obesity indicators are better predictors of metabolic risk?: healthy twin study. Obesity (Silver Spring). 2008;16(4):834–40.CrossRefGoogle Scholar
  24. 24.
    Kobayashi J, Murano S, Kawamura I, Nakamura F, Murase Y, Kawashiri MA, et al. The relationship of percent body fat by bioelectrical impedance analysis with blood pressure, and glucose and lipid parameters. J Atheroscler Thromb. 2006;13(5):221–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Malone M. Enhancing pharmacist involvement in weight management–time to get with the program. Ann Pharmacother. 2004;38(11):1961–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRefGoogle Scholar
  27. 27.
    Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001;96(2):325–31.PubMedCrossRefGoogle Scholar
  28. 28.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.PubMedCrossRefGoogle Scholar
  29. 29.
    Tsuyuki RT, Olson KL, Dubyk AM, Schindel TJ, Johnson JA. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med. 2004;116(2):130–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Ali F, Laurin MY, Lariviere C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol. 2003;10(3):101–6.PubMedGoogle Scholar
  31. 31.
    McKenney JM, Bradberry JC, Talbert RL, Cahill E, Brown WV. National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statintherapy, and pharmacists’ services. J Am Pharm Assoc. 2004;44(5):562–8.CrossRefGoogle Scholar
  32. 32.
    Dastani HB, Brown CM, O’Donnell DC. Combating the obesity epidemic: community pharmacists’ counseling on obesity management. Ann Pharmacother. 2004;38(11):1800–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Maram G. Katoue
    • 1
    Email author
  • Abdelmoneim I. Awad
    • 2
  • Samuel B. Kombian
    • 1
  1. 1.Department of Pharmacology and Therapeutics, Faculty of PharmacyKuwait UniversitySafatKuwait
  2. 2.Department of Pharmacy Practice, Faculty of PharmacyKuwait UniversitySafatKuwait

Personalised recommendations